In human colorectal cancer, the activation of p53 contributed to the inhibitory effects of estradiol and/or estrogen receptor agonists on the MMP-2/9 activity and migratory capacity, and p53 inhibitor could significantly block the anti-migration effects of estradiol and/or estrogen receptor [38]. Here, ESR1 is linked to colorectal cancer.